May 27 (Reuters) - Neuropace Inc NPCE.O:
NEUROPACE INC: REAFFIRMS ITS PREVIOUSLY ISSUED FULL-YEAR 2025 FINANCIAL GUIDANCE
NEUROPACE INC - COMPLETES PRIMARY ENDPOINT ANALYSIS FOR IDIOPATHIC GENERALIZED EPILEPSY STUDY
NEUROPACE INC - STUDY MEETS 12-WEEK POST-IMPLANT SAFETY ENDPOINT
NEUROPACE INC - PRELIMINARY DATA SHOWS FAVORABLE SEIZURE REDUCTION RATES FOR RNS SYSTEM
NEUROPACE - PRIMARY EFFECTIVENESS ENDPOINT NOT STATISTICALLY SIGNIFICANT IN OVERALL POPULATION
Source text: ID:nGNX8f1wL3
Further company coverage: NPCE.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.